Dong-A ST’s Anemia Biosimilar Darbecron Launches in the UAE
Dong-A ST has launched Darbecron, its second-generation anemia treatment biosimilar, in the United Arab Emirates (UAE), marking the first commercial rollout of the product in the Middle East and North Africa (MENA) region.The South Korean pharmaceutical company announced on October 12 that Darbecron, developed under the project name DA-3880, is now available in the UAE. Local regulatory approval…
Dong-A ST has launched its second-generation anemia treatment biosimilar, Darbecron, in the United Arab Emirates (UAE), marking the first commercial rollout of the product in the Middle East and North Africa (MENA) region. Developed under the project name DA-3880, the biosimilar is now available in the UAE, following local regulatory approval and commercialization handled by Julphar, a pharmaceutical company based in the UAE.
Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
